SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the World’s Next Generation Application for Drug Safety Administration
JERUSALEM, November 12, 2012 /PRNewswire/ –
SafeCode Drug Technologies Corp. (OTCBB: SAFC)(the “Company”), a developer of
patent-pending voice recognition technology that reduces the risks of errors during the
administration of prescription medications, is pleased to announce the launch of their new
website at http://www.safecodecorp.com. The website has been optimized for
accessibility and easy navigation on smartphones and tablets as well as laptops and home
In conjunction with the website unveiling, the Company has published a new video
demonstrating the SafeCode voice-activation technology as a novel product candidate for
the medical industry. Investors are encouraged to view the video on the Company’s website
or on YouTube at http://www.youtube.com/watch?v=PEy9ygT6jaA.
Across the past month, the Company has been granted eligibility status by the
Depository Trust Company and commenced trading on the OTC Bulletin Boards.
“We are dedicated to providing a high-quality product and transparency to our
stakeholders. We are taking all necessary steps to meet these corporate goals and doing so
in an expeditious manner,” said Joel Klopfer, Chief Executive Officer at SafeCode Drug
Technologies Corp. “Accidental deaths resulting from administering incorrect medication
represent a multi-billion-dollar area of unmet need. We believe that we have a solution
with our patent-pending voice-recognition technology that will benefit manufacturers,
pharmacists and patients while building our corporate value. This is an exciting time for
our company and shareholders as we enter the commercialization phase. The new website was
important to us as it showcases the SafeCode solution while giving investors fast,
user-friendly access to information on our company.”
About SafeCode Drug Technologies
SafeCode Drug Technologies Corporation is the developer of a patent-pending voice
recognition technology that provides an essential degree of security that can effectively
prevent unauthorized administration of a prescription medication.
This letter contains forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of
1934 as amended. All forward-looking statements are inherently uncertain, based on current
expectations and assumptions concerning future events or future performance of SafeCode
Drug Technologies Corp., and its technologies. In evaluating such statements, prospective
investors should review carefully various risks and uncertainties identified in this
release, as actual results may differ materially from those indicated. SafeCode Drug
Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact: Joel Klopfer Joel.Klofer1@gmail.com +972-2-5021322
SOURCE SafeCode Drug Technologies Corp.